Insider Selling: Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells 23,463 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 23,463 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total transaction of $168,933.60. Following the completion of the transaction, the chief executive officer directly owned 1,519,606 shares of the company’s stock, valued at approximately $10,941,163.20. This represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Fred Aslan also recently made the following trade(s):

• On Monday, October 5th, Fred Aslan sold 61,696 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $6.84, for a total value of $422,000.64.
• On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The shares were sold at an average price of $10.92, for a total value of $255,844.68.

Artiva Biotherapeutics Stock Performance

Artiva Biotherapeutics stock traded down $0.27 during trading on Wednesday, hitting $7.00. The company’s stock had a trading volume of 324,471 shares, compared to its average volume of 393,273. The stock’s fifty day moving average is $10.02 and its 200 day moving average is $9.23. Artiva Biotherapeutics, Inc. has a 1-year low of $2.71 and a 1-year high of $14.53. The stock has a market capitalization of $342.23 million, a price-to-earnings ratio of -2.12 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). On average, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ARTV has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $40.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. HC Wainwright reaffirmed a “buy” rating on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Wall Street Zen upgraded Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ARTV. BlackRock Inc. purchased a new position in Artiva Biotherapeutics in the second quarter valued at about $6,739,000. ADAR1 Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics in the second quarter worth about $1,151,000. Nantahala Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $2,910,000. Alyeska Investment Group L.P. grew its stake in shares of Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock valued at $2,654,000 after buying an additional 173,615 shares in the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $8,483,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.